Do analysts rate ITRM or CVKD?

Cadrenal Therapeutics has a consensus target price of $13.00, indicating a potential upside of 915.63%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cadrenal Therapeutics is more favorable than Iterum Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Cadrenal Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ITRM or CVKD more profitable?

Iterum Therapeutics' return on equity of 0.00% beat Cadrenal Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Iterum Therapeutics N/A N/A -65.54% Cadrenal Therapeutics N/A -406.41% -273.80%

Do analysts rate SNOA or ITRM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Do analysts rate ITRM or ENVB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ITRM or ENVB more profitable?

Iterum Therapeutics' return on equity of 0.00% beat Enveric Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Iterum Therapeutics N/A N/A -65.54% Enveric Biosciences N/A -168.04% -145.95%

Do analysts prefer NCNA or ITRM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is NCNA or ITRM more profitable?

Iterum Therapeutics' return on equity of 0.00% beat NuCana's return on equity. Company Net Margins Return on Equity Return on Assets NuCana N/A -41.90% -33.69% Iterum Therapeutics N/A N/A -65.54%

Do analysts recommend GELS or ITRM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has higher earnings and valuation, GELS or ITRM?

Gelteq has higher earnings, but lower revenue than Iterum Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gelteq $110K 86.97 -$4.30M N/A N/A Iterum Therapeutics $390K 4.10 -$24.77M -$0.75 N/A

Is GELS or ITRM more profitable?

Company Net Margins Return on Equity Return on Assets Gelteq N/A N/A N/A Iterum Therapeutics N/A N/A -65.54%

Iterum Therapeutics (ITRM) Competitors

$0.03 0.00 (0.00%)

As of 09/2/2026

Compare

ITRM vs. CVKD, SNOA, ENVB, NCNA, and GELS

Should you buy Iterum Therapeutics stock or one of its competitors? Iterum Therapeutics's main competitors and comparable companies include Cadrenal Therapeutics (CVKD), Sonoma Pharmaceuticals (SNOA), Enveric Biosciences (ENVB), NuCana (NCNA), and Gelteq (GELS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Iterum Therapeutics compare to Cadrenal Therapeutics?

Iterum Therapeutics (NASDAQ:ITRM) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

9.2% of Iterum Therapeutics shares are held by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are held by institutional investors. 2.0% of Iterum Therapeutics shares are held by insiders. Comparatively, 14.6% of Cadrenal Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cadrenal Therapeutics has lower revenue, but higher earnings than Iterum Therapeutics. Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$4.90	N/A

Cadrenal Therapeutics has a consensus target price of $13.00, indicating a potential upside of 915.63%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cadrenal Therapeutics is more favorable than Iterum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Cadrenal Therapeutics had 9 more articles in the media than Iterum Therapeutics. MarketBeat recorded 9 mentions for Cadrenal Therapeutics and 0 mentions for Iterum Therapeutics. Cadrenal Therapeutics' average media sentiment score of 0.76 beat Iterum Therapeutics' score of 0.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Iterum Therapeutics	Neutral
Cadrenal Therapeutics	Positive

Iterum Therapeutics' return on equity of 0.00% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
Cadrenal Therapeutics	N/A	-406.41%	-273.80%

Iterum Therapeutics has a beta of 2.96, meaning that its share price is 196% more volatile than the broader market. Comparatively, Cadrenal Therapeutics has a beta of 1.82, meaning that its share price is 82% more volatile than the broader market.

Summary

Iterum Therapeutics and Cadrenal Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Iterum Therapeutics compare to Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals (NASDAQ:SNOA) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

In the previous week, Sonoma Pharmaceuticals' average media sentiment score of 0.00 equaled Iterum Therapeutics'average media sentiment score.

Company	Overall Sentiment
Sonoma Pharmaceuticals	Neutral
Iterum Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Iterum Therapeutics has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -10.33%. Iterum Therapeutics' return on equity of 0.00% beat Sonoma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sonoma Pharmaceuticals	-10.33%	-21.41%	-6.08%
Iterum Therapeutics	N/A	N/A	-65.54%

2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are owned by institutional investors. 1.0% of Sonoma Pharmaceuticals shares are owned by insiders. Comparatively, 2.0% of Iterum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Sonoma Pharmaceuticals has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market. Comparatively, Iterum Therapeutics has a beta of 2.96, suggesting that its share price is 196% more volatile than the broader market.

Sonoma Pharmaceuticals has higher revenue and earnings than Iterum Therapeutics. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonoma Pharmaceuticals	$21.92M	0.29	-$3.17M	-$1.22	N/A
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A

Summary

Iterum Therapeutics beats Sonoma Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

How does Iterum Therapeutics compare to Enveric Biosciences?

Iterum Therapeutics (NASDAQ:ITRM) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Iterum Therapeutics' average media sentiment score of 0.00 equaled Enveric Biosciences'average media sentiment score.

Company	Overall Sentiment
Iterum Therapeutics	Neutral
Enveric Biosciences	Neutral

Iterum Therapeutics' return on equity of 0.00% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
Enveric Biosciences	N/A	-168.04%	-145.95%

Iterum Therapeutics has a beta of 2.96, indicating that its share price is 196% more volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

Enveric Biosciences has lower revenue, but higher earnings than Iterum Therapeutics. Enveric Biosciences is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A
Enveric Biosciences	N/A	N/A	-$8.77M	-$12.65	N/A

9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are owned by institutional investors. 2.0% of Iterum Therapeutics shares are owned by company insiders. Comparatively, 2.4% of Enveric Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Iterum Therapeutics beats Enveric Biosciences on 7 of the 10 factors compared between the two stocks.

How does Iterum Therapeutics compare to NuCana?

NuCana (NASDAQ:NCNA) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

44.0% of NuCana shares are owned by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are owned by institutional investors. 31.2% of NuCana shares are owned by company insiders. Comparatively, 2.0% of Iterum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, NuCana's average media sentiment score of 0.00 equaled Iterum Therapeutics'average media sentiment score.

Company	Overall Sentiment
NuCana	Neutral
Iterum Therapeutics	Neutral

Iterum Therapeutics' return on equity of 0.00% beat NuCana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-41.90%	-33.69%
Iterum Therapeutics	N/A	N/A	-65.54%

NuCana has a beta of 2.23, meaning that its stock price is 123% more volatile than the broader market. Comparatively, Iterum Therapeutics has a beta of 2.96, meaning that its stock price is 196% more volatile than the broader market.

Iterum Therapeutics has higher revenue and earnings than NuCana. NuCana is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$38.71M	-$3.81	N/A
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A

Summary

Iterum Therapeutics beats NuCana on 7 of the 10 factors compared between the two stocks.

How does Iterum Therapeutics compare to Gelteq?

Gelteq (NASDAQ:GELS) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

In the previous week, Gelteq had 1 more articles in the media than Iterum Therapeutics. MarketBeat recorded 1 mentions for Gelteq and 0 mentions for Iterum Therapeutics. Gelteq's average media sentiment score of 0.00 equaled Iterum Therapeutics'average media sentiment score.

Company	Overall Sentiment
Gelteq	Neutral
Iterum Therapeutics	Neutral

Gelteq has a beta of -0.41, indicating that its share price is 141% less volatile than the broader market. Comparatively, Iterum Therapeutics has a beta of 2.96, indicating that its share price is 196% more volatile than the broader market.

Gelteq has higher earnings, but lower revenue than Iterum Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gelteq	$110K	86.97	-$4.30M	N/A	N/A
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A

Company	Net Margins	Return on Equity	Return on Assets
Gelteq	N/A	N/A	N/A
Iterum Therapeutics	N/A	N/A	-65.54%

9.2% of Iterum Therapeutics shares are held by institutional investors. 2.0% of Iterum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Iterum Therapeutics beats Gelteq on 5 of the 9 factors compared between the two stocks.

Get Iterum Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ITRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ITRM vs. The Competition

Export

Metric	Iterum Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.60M	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-0.04	787.28	273.30	25.25
Price / Sales	4.10	755.95	618.15	97.66
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	-0.20	12.32	12.89	6.14
Net Income	-$24.77M	$2.82B	$3.47B	$349.01M
7 Day Performance	N/A	2.58%	0.53%	-0.31%
1 Month Performance	N/A	6.94%	5.64%	0.64%
1 Year Performance	N/A	9.44%	25.31%	14.83%

Iterum Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ITRM Iterum Therapeutics	0.042 of 5 stars	$0.03 flat	N/A	N/A	$1.60M	$390K	N/A	10
CVKD Cadrenal Therapeutics	2.3829 of 5 stars	$1.51 -13.7%	$13.00 +760.9%	-90.1%	$6.24M	N/A	N/A	4	Analyst Revision
SNOA Sonoma Pharmaceuticals	0.3852 of 5 stars	$1.29 flat	N/A	-71.4%	$6.18M	$19.53M	N/A	180
ENVB Enveric Biosciences	0.6778 of 5 stars	$1.37 flat	N/A	-88.6%	$6.13M	N/A	N/A	20
NCNA NuCana	0.8599 of 5 stars	$1.38 -6.1%	N/A	-53.0%	$6.12M	N/A	N/A	30	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ITRM) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Iterum Therapeutics (ITRM) Competitors

ITRM vs. CVKD, SNOA, ENVB, NCNA, and GELS

How does Iterum Therapeutics compare to Cadrenal Therapeutics?

Summary

How does Iterum Therapeutics compare to Sonoma Pharmaceuticals?

Summary

How does Iterum Therapeutics compare to Enveric Biosciences?

Summary

How does Iterum Therapeutics compare to NuCana?

Summary

How does Iterum Therapeutics compare to Gelteq?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ITRM vs. The Competition

Iterum Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Iterum Therapeutics (ITRM) Competitors

ITRM vs. CVKD, SNOA, ENVB, NCNA, and GELS

How does Iterum Therapeutics compare to Cadrenal Therapeutics?

Do institutionals & insiders hold more shares of ITRM or CVKD?

Which has preferable valuation & earnings, ITRM or CVKD?

Do analysts rate ITRM or CVKD?

Does the media favor ITRM or CVKD?

Is ITRM or CVKD more profitable?

Which has more volatility & risk, ITRM or CVKD?

Summary

How does Iterum Therapeutics compare to Sonoma Pharmaceuticals?

Does the media prefer SNOA or ITRM?

Do analysts rate SNOA or ITRM?

Is SNOA or ITRM more profitable?

Do insiders and institutionals hold more shares of SNOA or ITRM?

Which has more risk & volatility, SNOA or ITRM?

Which has preferable valuation and earnings, SNOA or ITRM?

Summary

How does Iterum Therapeutics compare to Enveric Biosciences?

Does the media refer more to ITRM or ENVB?

Is ITRM or ENVB more profitable?

Which has more risk and volatility, ITRM or ENVB?

Which has preferable earnings and valuation, ITRM or ENVB?

Do institutionals and insiders believe in ITRM or ENVB?

Do analysts rate ITRM or ENVB?

Summary

How does Iterum Therapeutics compare to NuCana?

Do analysts prefer NCNA or ITRM?

Do institutionals & insiders have more ownership in NCNA or ITRM?

Does the media prefer NCNA or ITRM?

Is NCNA or ITRM more profitable?

Which has more risk and volatility, NCNA or ITRM?

Which has higher earnings & valuation, NCNA or ITRM?

Summary

How does Iterum Therapeutics compare to Gelteq?

Does the media prefer GELS or ITRM?

Which has more risk and volatility, GELS or ITRM?

Which has higher earnings and valuation, GELS or ITRM?

Is GELS or ITRM more profitable?

Do institutionals and insiders have more ownership in GELS or ITRM?

Do analysts recommend GELS or ITRM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ITRM vs. The Competition

Iterum Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools